Usted buscó: secondarily (Inglés - Maltés)

and, secondarily,
u, sekondarjament,

a vessel, whatever its dimensions, used primarily or secondarily to take fisheries products,
bastiment, ta' kwalunkwe dimensjoni, li jintuża primarjament jew sekondarjament sabiex jieħu prodotti tas-sajd,

a vessel, whatever its dimensions, used primarily or secondarily to take fishery products;
bastiment, ta' kwalunkwe daqs, użat primarjament jew sekondarjament sabiex jieħu prodotti tas-sajd;

elvitegravir undergoes primarily oxidative metabolism via cyp3a, and is secondarily glucuronidated via ugt1a1/3 enzymes.
elvitegravir jgħaddi minn metaboliżmu primarju ossidattiv permezz ta’ cyp3a, u jiġi glukuronidat b’mod sekondarju permezz tal-enzimi ta’ ugt1a1/3.

in clinical studies of secondarily infected open wounds, the efficacy of retapamulin was inadequate in patients with infections caused by mrsa.
fi studji kliniċi dwar feriti infettati sekondarjament u miftuħa, l-effikaċja ta’ retapamulin ma kenitx adegwata f’pazjenti b’infezzjonijiet kawżati minn mrsa li jirreżisti l-metiċillina.

ertapenem was evaluated primarily for paediatric safety and secondarily for efficacy in randomized comparative, multicentre studies in patients 3 months to 17 years of age.
ertapenem kien evalwat l-ewwel għas-sigurtà pedjatrika u t-tieni għall-effikaċja fi studji randomized, komparattivi u multiċentriċi f'pazjenti ta' bejn it-3 xhur u s-17-il sena.

some cases of bleeding have occurred secondarily to tumour shrinkage and fistula formation, e.g. tracheo-oesophageal fistulae.
xi każijiet ta’ ħruġ ta’ demm seħħew b’mod sekondarju ma’ tumur li kien qed jiċkien u formazzjoni fistula, eż. fistuli trakeoesofagali.

efficacy in pediatric studies ertapenem was evaluated primarily for pediatric safety and secondarily for efficacy in randomized comparative, multicenter studies in patients 3 months to 17 years of age.
10 effikaċja fi studji pedjatriċi ertapenem kien evalwat l- ewwel għas- sigurtà pedjatrika u t- tieni għall- effikaċja fi studji randomized, komparattivi u multiċentriċi f' pazjenti ta 'bejn it- 3 xhur u s- 17- il sena.

single plasma samples were obtained from 516 adult and paediatric patients who received topical treatment with retapamulin 1% ointment twice daily for 5 days for the treatment of secondarily infected traumatic lesions.
kampjuni ta ’ plażma waħedhom ġew miksuba minn 516 adulti u pazjenti pedjatriċi li kienu ħadu trattament topiku b’ ingwent ta ’ 1% retapamulin darbtejn kuljum għal 5 jiem għat- trattament ta ’ feriti trawmatiċi infettati sekondarjament.

single plasma samples were obtained from 516 adult and paediatric patients who received topical treatment with retapamulin 10 mg/g ointment twice daily for 5 days for the treatment of secondarily infected traumatic lesions.
kampjuni ta’ plażma waħedhom ġew miksuba minn 516 adulti u pazjenti pedjatriċi li kienu ħadu trattament topiku b’ingwent ta’ 10 mg/g retapamulin darbtejn kuljum għal 5 jiem għat-trattament ta’ feriti trawmatiċi infettati sekondarjament.

health care insurance grants benefits in kind in the event of sickness, maternity or nonoccupational accidents (secondarily, if a person is not covered by accident insurance).
l-assikurazzjoni tal-kura tagħti l-benefiċċji mhux fi flus f’każ ta’ mard, maternità jew inċident mhux professjonali j) it-twelid fid-dar, fi sptar jew f’istituzzjoni ta’ kura simili għal ta’ sptar kif ukoll l-għajnuna ta’ tabib jew ta’ majjistra;

in clinical studies of secondarily infected open wounds, the efficacy of retapamulin was inadequate in patients with infections caused by methicillin-resistant staphylococcus aureus (mrsa).
retapamulin m’ għandux jintuża fit- trattament ta ’ infezzjonijiet magħrufa jew li jkunu ġejjin jew aktarx li jkunu ġejjin minn mrsa (ara sezzjoni 5. 1) fi studji kliniċi dwar feriti infettati sekondarjament u miftuħa, l- effikaċja ta ’ retapamulin ma kenitx adegwata f’ pazjenti b’ infezzjonijiet kawżati minn staphylococcus aureus (mrsa) li jirreżisti l- metiċillina.

after oral administration of 14c-labelled rasagiline, elimination occurred primarily via urine (62.6%) and secondarily via faeces (21.8%), with a total recovery of 84.4% of the dose over a period of 38 days.
84. 4% tad- doża kienet rikoverata fuq perjodu ta ’ 38 ġurnata.